<DOC>
	<DOC>NCT00711841</DOC>
	<brief_summary>Corticotherapy accelerates maternal postpartum recovery in women with class I HELLP syndrome. The benefit of faster and better recovery would be observed in fewer complications, less utilization of blood products and shorter hospital stay.</brief_summary>
	<brief_title>Effectivity of Postpartum Dexamethasone for Women With Class I HELLP Syndrome</brief_title>
	<detailed_description>Patients with Class I HELLP Syndrome will be recruited for use os dexamethasone or placebo in the puerperium. Effects such as clinical course (blood pressure and diureses), laboratorial behaviour and complications will be compared. Duration of hospitalization will also be accessed.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>HELLP Syndrome</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Postpartum women with Class I HELLP syndrome Chronic users of corticosteroids Patients with chronic conditions affecting the laboratory parameters involved in the HELLP syndrome Women who had received antenatal corticosteroids to treat HELLP syndrome were excluded</criteria>
	<gender>Female</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HELLP syndrome</keyword>
	<keyword>dexamethasone</keyword>
	<keyword>postpartum period</keyword>
	<keyword>class I HELLP syndrome</keyword>
</DOC>